Table 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

• Methylation-based ctDNA changes predict long-term clinical benefits in patients receiving immune checkpoint inhibitors.
• In a real-world pan-cancer study, about 60% of patients experienced significant clinical benefits based on tumor fraction changes.
• This observational study analyzed patient data to establish associations between ctDNA levels and treatment effects.
• Findings may enable personalized treatment approaches, improving outcomes for cancer patients across diverse types.